Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 63-73

  Schroeter, Marco R ^a   Humboldt, Tim ^a   Schäfer, Katrin ^a   Konstantinides, Stavros ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apolipoprotein E knockout mice; Atherosclerosis; Cell signalling; Progenitor cells; Statins

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E; ATAXIN 1; LECTIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PRAVASTATIN; PROTEIN KINASE B; ROSUVASTATIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW; BONE MARROW TRANSPLANTATION; BRACHIOCEPHALIC TRUNK; CELL COUNT; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HISTOGENESIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STEM CELL MOBILIZATION; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BETA-GALACTOSIDASE; BONE MARROW CELLS; CHEMOKINE CXCL12; FLUOROBENZENES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SIGNAL TRANSDUCTION; STEM CELLS; SULFONAMIDES;

EID: 67349263827     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.11.013     Document Type: Article

References (37)

1. Bea F., Blessing E., Bennett B., Levitz M., Wallace E.P., and Rosenfeld M.E. Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 22 (2002) 1832-1837
2. Werner N., Priller J., Laufs U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 22 (2002) 1567-1572
3. Chen Z., Fukutomi T., Zago A.C., et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 106 (2002) 20-23
4. Betteridge D.J., Gibson J.M., and Sager P.T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 100 (2007) 1245-1248
5. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
6. Schäfer K., Kaiser K., and Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost 93 (2005) 145-152
7. Erl W., Hristov M., Neureuter M., Yan Z.Q., Hansson G.K., and Weber P.C. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 169 (2003) 251-258
8. Indolfi C., Cioppa A., Stabile E., et al. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol 35 (2000) 214-221
9. Schonbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 109 (2004) II18-II26
10. Schafer A., Fraccarollo D., Vogt C., et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol 73 (2007) 1367-1375
11. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
12. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
13. Sata M., Saiura A., Kunisato A., et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8 (2002) 403-409
14. Schäfer K., Schroeter M.R., Dellas C., et al. Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol 26 (2006) 1254-1259
15. Schäfer K., Konstantinides S., Riedel C., et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation 106 (2002) 1847-1852
16. Wagner A.H., Kohler T., Ruckschloss U., Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
17. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14 (1994) 133-140
18. Paigen B., Morrow A., Holmes P.A., Mitchell D., and Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68 (1987) 231-240
19. Monetti M., Canavesi M., Camera M., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res 55 (2007) 441-449
20. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4 (2003) 9-14
21. Endo A., Tsujita Y., Kuroda M., and Tanzawa K. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 575 (1979) 266-276
22. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
23. Lindner V., Fingerle J., and Reidy M.A. Mouse model of arterial injury. Circ Res 73 (1993) 792-796
24. Ceradini D.J., Kulkarni A.R., Callaghan M.J., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10 (2004) 858-864
25. Yamaguchi J., Kusano K.F., Masuo O., et al. Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 107 (2003) 1322-1328
26. Zernecke A., Schober A., Bot I., et al. SDF-1alpha/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. Circ Res 96 (2005) 784-791
27. Shao H., Tan Y., Eton D., et al. Statin and stromal cell derived factor-1 additively promote angiogenesis by enhancement of progenitor cells incorporation into new vessels. Stem Cells (2008)
28. Mohle R., Bautz F., Rafii S., Moore M.A., Brugger W., and Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood 91 (1998) 4523-4530
29. Hattori K., Heissig B., Tashiro K., et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97 (2001) 3354-3360
30. Walter D.H., Haendeler J., Reinhold J., et al. Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease. Circ Res 97 (2005) 1142-1151
31. Zernecke A., Bot I., Talab Y.D., et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res (2007)
32. Thum T., Fraccarollo D., Galuppo P., et al. Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovasc Res 70 (2006) 50-60
33. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3 (2002) 687-694
34. Smadja D.M., Bieche I., Uzan G., et al. PAR-1 activation on human late endothelial progenitor cells enhances angiogenesis in vitro with upregulation of the SDF-1/CXCR4 system. Arterioscler Thromb Vasc Biol 25 (2005) 2321-2327
35. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
36. Liao J.K. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110 (2002) 285-288
37. Dimmeler S., Aicher A., Vasa M., et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108 (2001) 391-397